Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma

摘要: Glioblastoma Multiforme (GBM) is a highly malignant primary brain cancer that associated with abysmal prognosis. The median survival of GBM patients ∼15 months and there have not been any significant advance in therapies over decade, leaving treatment options limited. There clearly an unmet need for treatment. Immunotherapies are treatments based on usurping the power host's immune system to recognize eliminate cells. They recently proven be successful strategy combating variety cancers. Of various types immunotherapies, checkpoint blockade approaches thus far produced clinical responses several cancers including melanoma, non small-cell lung cancer, renal prostate cancer. This review focuses biological rationale using immunotherapeutic up-to-date summary current ongoing inhibitors-based trials glioma. In addition, we expand new concepts further improving treatments, particular focus advantages genetically engineered mouse models studies immunotherapies GBM. J. Cell. Biochem. 118: 2516-2527, 2017. © 2017 Wiley Periodicals, Inc.